These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Sonpavde G; Choueiri TK; Escudier B; Ficarra V; Hutson TE; Mulders PF; Patard JJ; Rini BI; Staehler M; Sternberg CN; Stief CG Eur Urol; 2012 Feb; 61(2):307-16. PubMed ID: 22055147 [TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma. Shinohara N; Abe T Int J Urol; 2015 Oct; 22(10):888-97. PubMed ID: 26147084 [TBL] [Abstract][Full Text] [Related]
12. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Costa LJ; Drabkin HA Oncologist; 2007 Dec; 12(12):1404-15. PubMed ID: 18165617 [TBL] [Abstract][Full Text] [Related]
13. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens. Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119 [TBL] [Abstract][Full Text] [Related]
14. Sequential use of targeted agents in the treatment of renal cell carcinoma. Hutson TE; Bukowski RM; Cowey CL; Figlin R; Escudier B; Sternberg CN Crit Rev Oncol Hematol; 2011 Jan; 77(1):48-62. PubMed ID: 20705477 [TBL] [Abstract][Full Text] [Related]
15. Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents. Coinu A; Petrelli F; Barni S Expert Rev Anticancer Ther; 2016; 16(1):33-43. PubMed ID: 26535485 [TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms. Mulders P BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190 [TBL] [Abstract][Full Text] [Related]
17. Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms. van der Mijn JC; Mier JW; Broxterman HJ; Verheul HM Drug Resist Updat; 2014; 17(4-6):77-88. PubMed ID: 25457974 [TBL] [Abstract][Full Text] [Related]
18. A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma. Funakoshi T; Lee CH; Hsieh JJ Cancer Treat Rev; 2014 May; 40(4):533-47. PubMed ID: 24398141 [TBL] [Abstract][Full Text] [Related]
19. The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma. Clement JM; McDermott DF Clin Genitourin Cancer; 2009 Aug; 7(2):E7-9. PubMed ID: 19692326 [TBL] [Abstract][Full Text] [Related]